Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-27 · 1381 Präparate · 72104 Quellenpassagen · 204 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Nebenwirkungen · Levetiracetam Actavis
Levetiracetam Actavis 250 mg film-coated tablets Levetiracetam Actavis 500 mg film-coated tablets Levetiracetam Actavis 750 mg film-coated tablets Levetiracetam Actavis 1000 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 10–11
HOS-215381 · Präparat HOS-155426
10
Frequency category
MedDRA SOC Very Common Uncommon Rare Very rare
common
Gastrointestinal Abdominal Pancreatitis
disorders pain,
diarrhoea,
dyspepsia,
vomiting,
nausea
Hepatobiliary Liver function Hepatic failure,
disorders test abnormal hepatitis
Renal and Acute Kidney
Urinary injury
Disorders
Skin and Rash Alopecia, Toxic epidermal
subcutaneous eczema, necrolysis,
tissue disorders pruritus, Stevens-Johnson
syndrome,
erythema
multiforme
Musculoskeleta Muscular Rhabdomyolysis
l and weakness, and blood
connective myalgia creatine
tissue disorders phosphokinase
increased(3)
General Asthenia/
disorders and fatigue
administration
site conditions
Injury, Injury
poisoning and
procedural
complications
(1)
See Description of selected adverse reactions.
(2)
Very rare cases of development of obsessive-compulsive disorders (OCD) in patients with
underlying history of OCD or psychiatric disorders have been observed in post-marketing
surveillance.
(3)
Prevalence is significantly higher in Japanese patients when compared to non-Japanese patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-26T11:59:00Z · SHA-256 916ec26b98afabaca46e661dbea86bf6238c924e4065aa7e8dde03fecd868db3 · Passage f25fa7800e6a940374bac8ebcf3615b14072148c8130ae12a3aba533c01d92b6 · Zeichen 5014–7340 im Abschnitt
Nebenwirkungen · Levetiracetam Actavis
Levetiracetam Actavis 250 mg film-coated tablets Levetiracetam Actavis 500 mg film-coated tablets Levetiracetam Actavis 750 mg film-coated tablets Levetiracetam Actavis 1000 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 11
HOS-215382 · Präparat HOS-155426
Description of selected adverse reactions
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-26T11:59:00Z · SHA-256 916ec26b98afabaca46e661dbea86bf6238c924e4065aa7e8dde03fecd868db3 · Passage f66db2a8100a521c1dea72ff90e696fa3846f9d5fcd6cf8e5e03ce5d71bde4a7 · Zeichen 7342–7383 im Abschnitt
Nebenwirkungen · Levetiracetam Actavis
Levetiracetam Actavis 250 mg film-coated tablets Levetiracetam Actavis 500 mg film-coated tablets Levetiracetam Actavis 750 mg film-coated tablets Levetiracetam Actavis 1000 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 11
HOS-215383 · Präparat HOS-155426
Multiorgan hypersensitivity reactions
Multiorgan hypersensitivity reactions (also known as Drug Reaction with Eosinophilia and Systemic
Symptoms, DRESS) have been reported rarely in patients treated with levetiracetam. Clinical
manifestations may develop 2 to 8 weeks after starting treatment. These reactions are variable in
expression, but typically present with fever, rash, facial oedema, lymphadenopathies, haematologic
abnormalities and can be associated with involvement of different organ systems, mostly the liver. If
multiorgan hypersensitivity reaction is suspected, levetiracetam should be discontinued.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-26T11:59:00Z · SHA-256 916ec26b98afabaca46e661dbea86bf6238c924e4065aa7e8dde03fecd868db3 · Passage eda55acf1b7364e2822fd26eda7705b641379bce3a142b173038200ed864c9d3 · Zeichen 7385–8000 im Abschnitt
Nebenwirkungen · Levetiracetam Actavis
Levetiracetam Actavis 250 mg film-coated tablets Levetiracetam Actavis 500 mg film-coated tablets Levetiracetam Actavis 750 mg film-coated tablets Levetiracetam Actavis 1000 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 11
HOS-215384 · Präparat HOS-155426
The risk of anorexia is higher when levetiracetam is coadministered with topiramate. In several cases
of alopecia, recovery was observed when levetiracetam was discontinued. Bone marrow suppression
was identified in some of the cases of pancytopenia.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-26T11:59:00Z · SHA-256 916ec26b98afabaca46e661dbea86bf6238c924e4065aa7e8dde03fecd868db3 · Passage ada828983ece5b00bc7dba4e5e55ff707162f43eac5bbc7ba9a7d3a438610c82 · Zeichen 8002–8252 im Abschnitt
Nebenwirkungen · Levetiracetam Actavis
Levetiracetam Actavis 250 mg film-coated tablets Levetiracetam Actavis 500 mg film-coated tablets Levetiracetam Actavis 750 mg film-coated tablets Levetiracetam Actavis 1000 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 11
HOS-215385 · Präparat HOS-155426
Cases of encephalopathy generally occurred at the beginning of the treatment (few days to a few
months) and were reversible after treatment discontinuation.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-26T11:59:00Z · SHA-256 916ec26b98afabaca46e661dbea86bf6238c924e4065aa7e8dde03fecd868db3 · Passage d6d19d8ebdd798df195944cae0b800bd88a0de18a20f5b56136a7a5174acde74 · Zeichen 8254–8410 im Abschnitt
Nebenwirkungen · Levetiracetam Actavis
Levetiracetam Actavis 250 mg film-coated tablets Levetiracetam Actavis 500 mg film-coated tablets Levetiracetam Actavis 750 mg film-coated tablets Levetiracetam Actavis 1000 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 11–12
HOS-215386 · Präparat HOS-155426
11
Paediatric population
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-26T11:59:00Z · SHA-256 916ec26b98afabaca46e661dbea86bf6238c924e4065aa7e8dde03fecd868db3 · Passage b07b5fe2813f39b0769a15480eb92a41dbd29a38217b581b229fd454da936a8b · Zeichen 8464–8489 im Abschnitt
Nebenwirkungen · Levetiracetam Actavis
Levetiracetam Actavis 250 mg film-coated tablets Levetiracetam Actavis 500 mg film-coated tablets Levetiracetam Actavis 750 mg film-coated tablets Levetiracetam Actavis 1000 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 12
HOS-215387 · Präparat HOS-155426
In patients aged 1 month to less than 4 years, a total of 190 patients have been treated with
levetiracetam in placebo-controlled and open label extension studies. Sixty of these patients were
treated with levetiracetam in placebo-controlled studies. In patients aged 4-16 years, a total of
645 patients have been treated with levetiracetam in placebo-controlled and open label extension
studies. 233 of these patients were treated with levetiracetam in placebo-controlled studies. In both
these paediatric age ranges, these data are supplemented with the post-marketing experience of the use
of levetiracetam.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-26T11:59:00Z · SHA-256 916ec26b98afabaca46e661dbea86bf6238c924e4065aa7e8dde03fecd868db3 · Passage 4013a1970bfd889f04715d4b9e5f220da64b6c671618821333b13328a28bc41f · Zeichen 8491–9101 im Abschnitt
Nebenwirkungen · Levetiracetam Actavis
Levetiracetam Actavis 250 mg film-coated tablets Levetiracetam Actavis 500 mg film-coated tablets Levetiracetam Actavis 750 mg film-coated tablets Levetiracetam Actavis 1000 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 12
HOS-215388 · Präparat HOS-155426
In addition, 101 infants aged less than 12 months have been exposed in a post authorization safety
study. No new safety concerns for levetiracetam were identified for infants less than 12 months of age
with epilepsy.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-26T11:59:00Z · SHA-256 916ec26b98afabaca46e661dbea86bf6238c924e4065aa7e8dde03fecd868db3 · Passage 41ed00d104d19c23174963c54848459e44b443ab02b058444d67ba507e1a8f21 · Zeichen 9103–9319 im Abschnitt
Nebenwirkungen · Levetiracetam Actavis
Levetiracetam Actavis 250 mg film-coated tablets Levetiracetam Actavis 500 mg film-coated tablets Levetiracetam Actavis 750 mg film-coated tablets Levetiracetam Actavis 1000 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 12
HOS-215389 · Präparat HOS-155426
The adverse reaction profile of levetiracetam is generally similar across age groups and across the
approved epilepsy indications. Safety results in paediatric patients in placebo-controlled clinical
studies were consistent with the safety profile of levetiracetam in adults except for behavioural and
psychiatric adverse reactions which were more common in children than in adults. In children and
adolescents aged 4 to 16 years, vomiting (very common, 11.2%), agitation (common, 3.4%), mood
swings (common, 2.1%), affect lability (common, 1.7%), aggression (common, 8.2%), abnormal
behaviour (common, 5.6%), and lethargy (common, 3.9%) were reported more frequently than in other
age ranges or in the overall safety profile. In infants and children aged 1 month to less than 4 years,
irritability (very common, 11.7%) and coordination abnormal (common, 3.3%) were reported more
frequently than in other age groups or in the overall safety profile.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-26T11:59:00Z · SHA-256 916ec26b98afabaca46e661dbea86bf6238c924e4065aa7e8dde03fecd868db3 · Passage 3ccbb326e277875bb9e9adba92b52f6b30b4ee52e2944d22c34697927788270d · Zeichen 9321–10270 im Abschnitt
Nebenwirkungen · Levetiracetam Actavis
Levetiracetam Actavis 250 mg film-coated tablets Levetiracetam Actavis 500 mg film-coated tablets Levetiracetam Actavis 750 mg film-coated tablets Levetiracetam Actavis 1000 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 12
HOS-215390 · Präparat HOS-155426
A double-blind, placebo-controlled paediatric safety study with a non-inferiority design has assessed
the cognitive and neuropsychological effects of levetiracetam in children 4 to 16 years of age with
partial onset seizures. It was concluded that levetiracetam was not different (non inferior) from
placebo with regard to the change from baseline of the Leiter-R Attention and Memory, Memory
Screen Composite score in the per-protocol population. Results related to behavioural and emotional
functioning indicated a worsening in levetiracetam treated patients on aggressive behaviour as
measured in a standardised and systematic way using a validated instrument (CBCL – Achenbach
Child Behaviour Checklist). However subjects, who took levetiracetam in the long-term open label
follow-up study, did not experience a worsening, on average, in their behavioural and emotional
functioning; in particular measures of aggressive behaviour were not worse than baseline.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-26T11:59:00Z · SHA-256 916ec26b98afabaca46e661dbea86bf6238c924e4065aa7e8dde03fecd868db3 · Passage 130a731f3901fdb89450051077a5535b58798de5a40f754fba69b682cf745e5c · Zeichen 10272–11235 im Abschnitt
Nebenwirkungen · Levetiracetam Actavis
Levetiracetam Actavis 250 mg film-coated tablets Levetiracetam Actavis 500 mg film-coated tablets Levetiracetam Actavis 750 mg film-coated tablets Levetiracetam Actavis 1000 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 12
HOS-215391 · Präparat HOS-155426
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It
allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via the national reporting system
listed in Appendix V.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-26T11:59:00Z · SHA-256 916ec26b98afabaca46e661dbea86bf6238c924e4065aa7e8dde03fecd868db3 · Passage 42f7144177697b690f59b1bda795c3fd216297691cf296a2e1269a137feab3cd · Zeichen 11237–11592 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.